Bris­tol My­ers Squibb sues No­var­tis for roy­al­ties sur­round­ing the use of trans­genic mice

Two Big Phar­ma com­pa­nies are go­ing to the mat over ge­net­i­cal­ly mod­i­fied mice in a li­cens­ing dis­pute.

Bris­tol My­ers Squibb is su­ing No­var­tis in New York over a dis­pute con­cern­ing an eval­u­a­tion, re­search and com­mer­cial­iza­tion agree­ment stretch­ing back to the late ’90s ini­tial­ly inked be­tween No­var­tis and BMS’ pre­de­ces­sor Medarex. The deal in ques­tion al­lowed No­var­tis to use Medarex’s patent­ed trans­genic mice to de­vel­op ther­a­peu­tic drugs. No­var­tis agreed to pay Medarex – and sub­se­quent­ly BMS – a roy­al­ty on sales of drugs it de­vel­oped us­ing the mice.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.